Advertisement

Inclusion of pregnant and breastfeeding women in nonobstetrical randomized controlled trials

      BACKGROUND

      There is an urgent need to prioritize and expedite the inclusion of pregnant and breastfeeding women in research. Characterizing trials that have successfully included these populations could inform the design and execution of future studies. In addition, up-to-date data on their inclusion in clinical research could assist in setting benchmarks, establishing targets, and monitoring progress toward more equitable inclusion.

      OBJECTIVE

      This study aimed to characterize the eligibility and enrollment of pregnant and breastfeeding women in randomized controlled trials evaluating interventions for nonobstetrical conditions experienced by, but not limited to, these populations.

      STUDY DESIGN

      We developed a literature search in collaboration with an information specialist. We included randomized controlled trials published between 2017 and 2019 in the 5 highest-impact general medicine journals and the 3 highest-impact specialty journals in cardiovascular disease, critical care, general infectious diseases, HIV, and psychiatry. We included randomized controlled trials that evaluated screening, diagnosis, prevention, or treatment of nonobstetrical medical conditions. We excluded randomized controlled trials exclusively focused on males, pediatrics, geriatrics, oncology, or postmenopausal women, and publications reporting subgroup, pooled, or follow-up analyses of previously published randomized controlled trials. We screened titles and abstracts independently and in duplicate, with discrepancies resolved by a third reviewer. We entered data into a standardized electronic case report form. We reviewed study protocols, appendices, and trial registries for additional data.

      RESULTS

      Of the 1333 randomized controlled trials, pregnant and breastfeeding women were eligible for 13 (1.0%) and 6 (0.5%), respectively. Pregnancy and breastfeeding eligibility criteria were not addressed in 383 of 1333 (28.7%) and 710 of 1333 (53.3%) randomized controlled trials, respectively. In total, 102 of 937 (10.9%) and 33 of 617 (5.3%) randomized controlled trials that explicitly excluded pregnant and breastfeeding women documented the rationale. Most studies excluding pregnant women (542/937; 57.8%) required at least 1 method of contraception and/or pregnancy testing as part of trial participation for women with reproductive capacity. Among the 13 randomized controlled trials that allowed inclusion of pregnant women, 3 restricted eligibility to specific trimesters. Two randomized controlled trials enrolled pregnant women after the first year of the study following interim review of safety results in nonpregnant participants. Four randomized controlled trials reported the number of pregnant women enrolled, which ranged from 0.7% to 3.4% of the study population. None of the studies reported on pregnancy or perinatal outcomes. Compared with randomized controlled trials that excluded pregnant women, those including them more commonly had an infectious disease focus (12/13 [92.3%] vs 270/937 [28.8%]; p<.0001), including HIV (5/13 [38.5%] vs 96/937 [10.2%]; p=.0079), enrolled participants in sub-Saharan Africa (5/13 [38.5%] vs 111/937 [11.8%]; p=.0143), and had exclusively nonindustry sponsorship (13/13 [100%] vs 559/937 [59.7%]; p=.0025); inclusion varied by study phase, randomization level, and intervention type.

      CONCLUSION

      This study illustrates a major inequity in research involving pregnant and breastfeeding women. As new health challenges arise, including novel pandemics, and the research community mobilizes to develop therapies and innovate in patient care, it is crucial that pregnant and breastfeeding women not be left behind. Greater regulatory support, in the form of explicit requirements and incentives, will be needed to ensure these populations are integrated into the research agenda.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology MFM
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • van der Zande ISE
        • van der Graaf R
        • Oudijk MA
        • van Delden JJM.
        Vulnerability of pregnant women in clinical research.
        J Med Ethics. 2017; 43: 657-663
        • Briggs GG
        • Polifka JE
        • Wisner KL
        • et al.
        Should pregnant women be included in phase IV clinical drug trials?.
        Am J Obstet Gynecol. 2015; 213: 810-815
        • Kassebaum NJ
        • Bertozzi-Villa A
        • Coggeshall MS
        • et al.
        Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.
        Lancet. 2014; 384: 980-1004
        • Howard LM
        • Khalifeh H.
        Perinatal mental health: a review of progress and challenges.
        World Psychiatry. 2020; 19: 313-327
      1. CADTH database search filters [internet]. Available at: https://searchfilters.cadth.ca/. Accessed December 1, 2020.

        • Harris PA
        • Taylor R
        • Thielke R
        • Payne J
        • Gonzalez N
        • Conde JG.
        Research Electronic Data Capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support.
        J Biomed Inform. 2009; 42: 377-381
        • Smith DD
        • Pippen JL
        • Adesomo AA
        • Rood KM
        • Landon MB
        • Costantine MM.
        Exclusion of pregnant women from clinical trials during the coronavirus disease 2019 pandemic: a review of international registries.
        Am J Perinatol. 2020; 37: 792-799
        • Phelan AL
        • Kunselman AR
        • Chuang CH
        • Raja-Khan NT
        • Legro RS.
        Exclusion of women of childbearing potential in clinical trials of type 2 diabetes medications: a review of protocol-based barriers to enrollment.
        Diabetes Care. 2016; 39: 1004-1009
        • Shields KE
        • Lyerly AD.
        Exclusion of pregnant women from industry-sponsored clinical trials.
        Obstet Gynecol. 2013; 122: 1077-1081
      2. Dhand NK, Khatkar MS. Statulator: an online statistical calculator. Sample size calculator for estimating a single proportion. 2014. Available at: http://statulator.com/SampleSize/ss1P.html. Accessed November 3, 2020.

        • Shehabi Y
        • Serpa Neto A
        • Howe BD
        • et al.
        Early sedation with dexmedetomidine in ventilated critically ill patients and heterogeneity of treatment effect in the SPICE III randomised controlled trial.
        Intensive Care Med. 2021; 47: 455-466
        • Lv J
        • Zhang H
        • Wong MG
        • et al.
        Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial.
        JAMA. 2017; 318: 432-442
        • Wang HE
        • Schmicker RH
        • Daya MR
        • et al.
        Effect of a strategy of initial laryngeal tube insertion vs endotracheal intubation on 72-hour survival in adults with out-of-hospital cardiac arrest: a randomized clinical trial.
        JAMA. 2018; 320: 769-778
        • McDermott MM
        • Ferrucci L
        • Tian L
        • et al.
        Effect of granulocyte-macrophage colony-stimulating factor with or without supervised exercise on walking performance in patients with peripheral artery disease: the PROPEL randomized clinical trial.
        JAMA. 2017; 318: 2089-2098
        • Cahill KN
        • Katz HR
        • Cui J
        • et al.
        KIT inhibition by imatinib in patients with severe refractory asthma.
        N Engl J Med. 2017; 376: 1911-1920
        • Johnston KC
        • Bruno A
        • Pauls Q
        • et al.
        Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke: the SHINE randomized clinical trial.
        JAMA. 2019; 322: 326-335
        • McManus RJ
        • Mant J
        • Franssen M
        • et al.
        Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial.
        Lancet. 2018; 391: 949-959
        • Venter WDF
        • Moorhouse M
        • Sokhela S
        • et al.
        Low-dose ritonavir-boosted Darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.
        Lancet HIV. 2019; 6: e428-e437
        • Llanos-Cuentas A
        • Lacerda MVG
        • Hien TT
        • et al.
        Tafenoquine versus primaquine to Prevent Relapse of Plasmodium vivax Malaria.
        N Engl J Med. 2019; 380: 229-241
        • Investigators J-DAVID
        • Shoji T
        • Inaba M
        • et al.
        Effect of Oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism receiving maintenance hemodialysis: The J-DAVID Randomized Clinical Trial.
        JAMA. 2018; 320: 2325-2334
        • Beigel JH
        • Aga E
        • Elie-Turenne MC
        • et al.
        Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.
        Lancet Respir Med. 2019; 7: 941-950
        • Beigel JH
        • Tebas P
        • Elie-Turenne MC
        • et al.
        Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study.
        Lancet Respir Med. 2017; 5: 500-511
        • Daum RS
        • Miller LG
        • Immergluck L
        • et al.
        A placebo-controlled trial of antibiotics for smaller skin abscesses.
        N Engl J Med. 2017; 376: 2545-2555
        • Grant AD
        • Charalambous S
        • Tlali M
        • et al.
        Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial.
        Lancet HIV. 2020; 7: e27-e37
        • Hayes RJ
        • Donnell D
        • Floyd S
        • et al.
        Effect of universal testing and treatment on HIV incidence - HPTN 071 (PopART).
        N Engl J Med. 2019; 381: 207-218
        • Iglesias JF
        • Muller O
        • Heg D
        • et al.
        Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
        Lancet. 2019; 394: 1243-1253
        • Makhema J
        • Wirth KE
        • Pretorius Holme M
        • et al.
        Universal testing, expanded treatment, and incidence of HIV infection in Botswana.
        N Engl J Med. 2019; 381: 230-242
        • Marks M
        • Toloka H
        • Baker C
        • et al.
        Randomized trial of community treatment with azithromycin and ivermectin mass drug administration for control of scabies and impetigo.
        Clin Infect Dis. 2019; 68: 927-933
        • Miller WC
        • Hoffman IF
        • Hanscom BS
        • et al.
        A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study.
        Lancet. 2018; 392: 747-759
        • Mulangu S
        • Dodd LE
        • Davey Jr, RT
        • et al.
        A randomized, controlled trial of Ebola virus disease therapeutics.
        N Engl J Med. 2019; 381: 2293-2303
        • Ngwira LG
        • Corbett EL
        • Khundi M
        • et al.
        Screening for tuberculosis with Xpert MTB/RIF assay versus fluorescent microscopy among adults newly diagnosed with human immunodeficiency virus in rural Malawi: a cluster randomized trial (Chepetsa).
        Clin Infect Dis. 2019; 68: 1176-1183
        • Radonovich LJ
        • Jr Simberkoff MS
        • Bessesen MT
        • et al.
        N95 respirators vs medical masks for preventing influenza among health care personnel: a randomized clinical trial.
        JAMA. 2019; 322: 824-833
        • Sutanto I
        • Kosasih A
        • Elyazar IRF
        • et al.
        Negligible impact of mass screening and treatment on mesoendemic malaria transmission at west Timor in Eastern Indonesia: a cluster-randomized trial.
        Clin Infect Dis. 2018; 67: 1364-1372
        • Taylor MM
        • Kobeissi L
        • Kim C
        • et al.
        Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action.
        Lancet Glob Health. 2021; 9: e366-e371
        • Pariente G
        • Leibson T
        • Carls A
        • Adams-Webber T
        • Ito S
        • Koren G.
        Pregnancy-associated changes in pharmacokinetics: a systematic review.
        PLoS Med. 2016; 13e1002160
        • Andrade SE
        • Gurwitz JH
        • Davis RL
        • et al.
        Prescription drug use in pregnancy.
        Am J Obstet Gynecol. 2004; 191: 398-407
        • Daw JR
        • Hanley GE
        • Greyson DL
        • Morgan SG.
        Prescription drug use during pregnancy in developed countries: a systematic review.
        Pharmacoepidemiol Drug Saf. 2011; 20: 895-902
        • Leong C
        • Chateau D
        • Dahl M
        • et al.
        Prescription medication use during pregnancies that resulted in births and abortions (2001-2013): a retrospective population-based study in a Canadian population.
        PLoS One. 2019; 14e0211319
        • Adam MP
        • Polifka JE
        • Friedman JM.
        Evolving knowledge of the teratogenicity of medications in human pregnancy.
        Am J Med Genet C Semin Med Genet. 2011; 157C: 175-182
        • Little BB.
        Pharmacokinetics during pregnancy: evidence-based maternal dose formulation.
        Obstet Gynecol. 1999; 93: 858-868
        • Andrew MA
        • Easterling TR
        • Carr DB
        • et al.
        Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies.
        Clin Pharmacol Ther. 2007; 81: 547-556
        • Zipursky JS
        • Greenberg RA
        • Maxwell C
        • Bogler T.
        Pregnancy, breastfeeding and the SARS-CoV-2 vaccine: an ethics-based framework for shared decision-making.
        CMAJ. 2021; 193: E312-E314
      3. Institute for Clinical Evaluative Sciences. ICES COVID-19 Dashboard. Available at: https://www.ices.on.ca/DAS/AHRQ/COVID-19-Dashboard#priority-groups. Accessed November 5, 2021.

      4. Scicione AC. 40 years of leading maternal and fetal care: our journey together. 2013. Available at: https://s3.amazonaws.com/cdn.smfm.org/media/1819/SMFM_AllChapters.pdf. Accessed June 29, 2021.

        • National Institutes of Health
        NIH guidelines on the inclusion of women and minorities as subjects in clinical research.
        NIH guide to grants and contracts. National Institutes of Health, Washington, DC1994: 94-100
      5. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Pregnant women: scientific and ethical considerations for inclusion in clinical trials guideance for industry. 2018. Available at: https://www.fda.gov/media/112195/download. Accessed June 29, 2021.

      6. International Ethical Guidelines for health-related research Involving Humans. Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO). 2016. Available at: https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf. Accessed June 29, 2021.

      7. Office for Human Research Protections. Additional protections for pregnant women, human fetuses and neonates involved in research, subpart B. 45 CFR 46. 2021. Available at: https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46. Accessed November 4, 2021.

      8. Task force on research specific to pregnant women and lactating women. Report to Secretary. Health and Human Services Congress; 2018. Available at: https://www.nichd.nih.gov/about/advisory/PRGLAC. Accessed November 4, 2021

        • Krubiner CB
        • Faden RR
        • Cadigan RJ
        • et al.
        Advancing HIV research with pregnant women: navigating challenges and opportunities.
        AIDS. 2016; 30: 2261-2265
        • Wickremsinhe MN
        • Little MO
        • Carter AS
        • Sullivan KA
        • Lyerly AD.
        Beyond “vessels and vectors”: a global review of registered HIV-related clinical trials with pregnant women.
        J Womens Health (Larchmt). 2019; 28: 93-99
        • Faden R
        • Kass N
        • McGraw D.
        Women as vessels and vectors: lessons from the HIV epidemic.
        (ed)in: Wolf SM Feminism and bioethics: beyond reproduction. Oxford University Press, New York, NY1996
      9. The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network. IMPAACT at International Workshop on HIV pediatrics 2022 and AIDS 2022. 2022. Available at: https://www.impaactnetwork.org/. Accessed July 14, 2022.

        • Angelidou K
        • Fowler MG
        • Flynn P
        • et al.
        Enrollment and transition challenges in the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) network's PROMISE trial for resource-limited regions.
        Clin Trials. 2020; 17: 437-447
        • Zimmerman K
        • Gonzalez D
        • Swamy GK
        • Cohen-Wolkowiez M.
        Pharmacologic studies in vulnerable populations: using the pediatric experience.
        Semin Perinatol. 2015; 39: 532-536
      10. A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) - COVID-19 pandemic appendix. Available at: https://www.remapcap.org/coronavirus. Accessed 7 July 2021.

      11. World Health Organization. Solidarity clinical trial for COVID-19 treatments. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments. Accessed 7 July 2021.

      12. University of Oxford. Randomized evaluation of COVID-19 therapy (RECOVERY) protocol v15.0 2021-04-12. Available at: https://www.recoverytrial.net/files/recovery-protocol-v15-0-2021-04-12.pdf. Accessed 5 July 2021.

        • Scaffidi J
        • Mol BW
        • Keelan JA.
        The pregnant women as a drug orphan: a global survey of registered clinical trials of pharmacological interventions in pregnancy.
        BJOG. 2017; 124: 132-140
        • Payne P.
        Including pregnant women in clinical research: practical guidance for institutional review boards.
        Ethics Hum Res. 2019; 41: 35-40